Navigation Links
RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
Date:4/11/2008

n addition to closing on Fund II, RiverVest Venture Partners announced that John P. McKearn, Ph.D., has joined the firm as Venture Partner.

Dr. McKearn brings 25 years of scientific and operational expertise in pharmaceutical research and development at Kalypsys, Inc., Pharmacia, G.D. Searle & Co., and E.I. DuPont de Nemours and Company.

"We've known John since Pfizer bought Pharmacia back in 2003 and have kept in close contact ever since," said Mr. Schmelter. "John's strong scientific training and operational expertise will further our capabilities in sourcing and adding value to our biopharmaceutical portfolio."

While leading Kalypsys, Inc., a privately held biotechnology company in San Diego, Dr. McKearn raised more than $150 million in private equity from 2003-2006. As head of Research for Searle and Pharmacia, Dr. McKearn was an important contributor to the discovery, development and launch of no fewer than eight new prescription drugs, including Celebrex, one of the leading pharmaceuticals to treat arthritis.

"I believe in the quality of RiverVest's personnel, investors and portfolio, along with their vast industry and academic networks," said Dr. McKearn. "Fund I has had an impressive track record, and I look forward to applying my expertise to building RiverVest's biopharmaceutical presence."

Dr. McKearn holds a Ph.D. in immunology from the University of Chicago and a B.S. in biology from Northern Illinois University. He currently serves as a member of the board of directors for IDM Pharma (formerly Epimmune) and for Keel Pharmaceuticals.

About RiverVest Venture Partners

RiverVest Venture Partners is a venture capital firm investing in promising life sciences companies nationwide. RiverVest applies both its capital and its team's diverse range of expertise to create and grow successful enterprises that address unmet medical needs in major markets. RiverVest's extensive national network and privileged access to
'/>"/>

SOURCE RiverVest Venture Partners
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. Biopure Gives Update on Malaysia Joint Venture Discussions
3. Hank Plain Joins Morgenthaler Ventures as Partner
4. Dan Broderick Joins Prolog Ventures as Partner
5. DiObex Inc. to Present at BIO Mid-America Venture Forum
6. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
7. Altheus Therapeutics Secures $3.6 Million in Venture Capital
8. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
9. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...recently announced that Dr. Dominique Hebrault wil...ss Analytical Technology (PAT) in Green Chemistry ... , (PRWEB) November 20, 20...echnology (PAT) in Green Chemistry and Green Engin...Technology (PAT) case studies will be presented on...
(Date:11/19/2009)...swire/ -- Dr. Mate Hidvegi, inventor of Avemar fer...ease issued on November 17 by Biropharma Kft, disc...d self-serving statements about its U.S. competito...from his office in Budapest, Hungary: ,, "The ...apply to AveULTRA, www.aveultra.com , is mislea...
(Date:11/19/2009)...Mass., Nov. 19 Arlington Medical R...e leading driver of antibiotic selection in nosoco...y against gram-positive and gram-negative pathogen...nosocomial pneumonia, surveyed European physicians...rovide appropriate coverage against common pathoge...
(Date:11/19/2009)...e Synthesis Companies Form International Gene Synt...es in Risk Reduction ,Five Member Companies Repr...ity , (PRWEB) November 19...ynthesis companies today announced agreement that ...mote biosecurity in the gene synthesis industry. ...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
..., December 11 , - New ,Trophon EPR, Device ...ultrasound transducer disinfection are in many cas...he latest alarming result,issued by the Center for... US,public health agency, in its recently publishe...Healthcare Facilities (1). The guideline is the CD...
...1 Delcath Systems, Inc. (Nasdaq: DCTH ), a me...ercutaneous Hepatic Perfusion ("PHP") System for t...day that the first fifty percent (46 of 92) of pat... trial treating metastatic cutaneous and ocular me...cer centers in this trial continue to evaluate and...
... Alimera Sciences Inc., a privately held,biopharm..., development and,commercialization of prescriptio...enrollment has begun for a pilot study to assess t...with bilateral geographic atrophy (GA) secondary t...The pilot study will compare two doses of Iluvien ...
Other Biology Technology:Ultrasound Transducer Disinfection in Many Cases Insufficient 2Ultrasound Transducer Disinfection in Many Cases Insufficient 3Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2
(Date:11/19/2009)... with an unwieldy name: 4-hydroxybutyrate (4-HB). ...-rape drug. , Now, a team of Ohio and Michigan ...B is metabolized by the body. "This is new and imp...ssor and chair of biological sciences at Michigan ...rch team. "It may provide new clues on how to cou...
(Date:11/19/2009)...2: The offspring of two inbred strains tend to be ...the gene-level variability that leads to this phen...boost our ability to custom-tailor crops for speci... consumption or high glucose content for biomass f...quence of the common corn strain B73, University o...
(Date:11/19/2009)...nable farming, initially adopted to preserve soil ...le in maintaining a healthy climate, according to ...e and Los Alamos national laboratories. , ORNL a...al of the earth,s soils to sequester carbon, with ...ld greatly reduce U.S. carbon emissions by as much...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 3Seattle Childrens Hospital Deploys CAs Integrated Infrastructure and Performance Management Solution 52930 1Seattle Childrens Hospital Deploys CAs Integrated Infrastructure and Performance Management Solution 52930 2Seattle Childrens Hospital Deploys CAs Integrated Infrastructure and Performance Management Solution 52930 3Abbott to Acquire Nutrition Businesses Expanding Presence in India 52926 1Abbott to Acquire Nutrition Businesses Expanding Presence in India 52926 2Abbott to Acquire Nutrition Businesses Expanding Presence in India 52926 3Must Haves for Your Summer Vacation Bag 52922 1Must Haves for Your Summer Vacation Bag 52922 2Must Haves for Your Summer Vacation Bag 52922 3
...ma Barkai will receive the Helen and Martin Kimmel.... 5 at the Weizmann Institute. The award is accomp...r five years. , Taking a chance on an experiment ... Living cells are, from this angle, great subjects...have all sorts of interesting consequences for man...
...e in the November 2007 issue of BioScience describ...llenges of green roofsroofs with a vegetated surfa...struct than a typical roof, a green roof can reduc...trol storm-water runoff. Green roofs also provide ... less common in the United States than in Japan an...
... Far removed from streams of gas-thirsty cars and ...er in global climate change. Circling the norther... - one of the largest ecosystems on earth - act as...vels. , Forest ecologists at the University of Wi...tors such as forest fires and climate influence ca...
Other Biology News:Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2Wildfire drives carbon levels in northern forests 2
CORNING ROLLER BOTTLES, 850 CM2, PS, EASY GRIP CAP, STERILE from Sigma-Aldrich
...n be upgraded to the GenePix Autoloader 4200AL. Th...nalyzes, and saves results for up to 36 slides, th...e. Line-by-line autofocus ensures superior field u...es you complete flexibility to configure scanning ...
...rray data using Asuragens bioinformatics expertise...to extensive data analysis using the most up to da...ith the Gene Expression Profiling Service or from ...on and basic statistical analysis including public...
Illumina Custom Data Analysis Report from Asuragen, Inc.
Biology Products: